BOCH
LENZ

Blue Owl Capital Holdings’s LENZ Therapeutics LENZ Stock Holding History

Blue Owl Capital Holdings’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.3M Buy
756,722
+250,000
+49% +$2.02M 0.65% 27
2026
Q1 		$4.64M Buy
506,722
+356,722
+238% +$5.01M 1.25% 21
2025
Q4 		$2.4M Buy
+150,000
New +$4.37M 0.74% 33

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Blue Owl Capital Holdings's LENZ Position: Q2 2026 in Review

Blue Owl Capital Holdings increased its LENZ Therapeutics (LENZ) stake by 49% in Q2 2026, buying an estimated $2.02M and bringing the position to 756,722 shares worth $4.3M. The position accounts for 0.65% of the portfolio, ranked #27.

Blue Owl Capital Holdings first reported a position in LENZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.64M in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Blue Owl Capital Holdings held 756,722 shares of LENZ Therapeutics worth $4.3M as of Q2 2026.
  • Blue Owl Capital Holdings bought 250,000 LENZ Therapeutics shares in Q2 2026, an estimated $2.02M.
  • LENZ Therapeutics made up 0.65% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #27 holding.
  • Blue Owl Capital Holdings first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Blue Owl Capital Holdings's LENZ Therapeutics position peaked at $4.64M in Q1 2026.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.